A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)

General Information

Summary This is a study of transplantation of Astrocytes derived from human embryonic stem cells, in patients with Amyotrophic Lateral Sclerosis (ALS). There will be no change in the routine ALS treatment of the patients enrolled into the study. Treatment will be administered in addition to the appropriate standard of care treatment. The study hypothesis is that transplantation of Astrocyte(AstroRx) cells can compensate for the malfunctioning of patients' own astrocytes by restoring physiological capabilities like the reuptake of excessive glutamate, reducing oxidative stress, reducing other toxic compounds, as well as by secreting different neuroprotective factors
Clinical trials phase Phases 1/2
Start date (estimated) 2018-04-12
End date (estimated) 2020-08-31
Clinical feature
Label Amyotrophic Lateral Sclerosis
Link http://purl.obolibrary.org/obo/NCIT_C34373
Description A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.

Administrative Information

NCT Number NCT03482050
Other study identifiers
Name ASTRO-001-IL
Source weblink https://clinicaltrials.gov/ct2/show/NCT03482050
Regulatory body approval
Country
Public contact
Email HCRC_ALS@hadassah.org.il
Public email HCRC_ALS@hadassah.org.il
First name Yael
Last name Feinsod
Phone +972-2-6779372
Country
Israel
Sponsors Kadimastem

Cell Line

Recruitment

Recruitment Status Recruiting
Estimated number of participants 21